In a recent WIRED article, LegitScript Director of Research and Trust & Safety Counsel Gerard Olson says that even if the FDA moves forward with reclassifying certain peptides, the change will not immediately open the market, as the agency must first complete a formal rulemaking and public comment process. He notes that the regulatory timeline underscores the importance of careful oversight as telehealth providers and pharmacies prepare for growing demand for peptide therapies.
